| 1 |
Yasmin F, Najeeb H, Naeem U, Moeed A, Koritala T, Surani S. Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease. World J Clin Cases 2022; 10(21): 7195-7208 [DOI: 10.12998/wjcc.v10.i21.7195] [Reference Citation Analysis]
|
| 2 |
Vasile Balaban D, Jinga M. Apheresis in Inflammatory Bowel Disease: Current Evidence. Crohn’s Disease Recent Advances 2021. [DOI: 10.5772/intechopen.93605] [Reference Citation Analysis]
|
| 3 |
Woźniak M, Kurnatowska I, Małecka-Panas E, Talar-Wojnarowska R. Leukocytapheresis in patients with inflammatory bowel diseases. Prz Gastroenterol 2021;6:99-105. [PMID: 34276835 DOI: 10.5114/pg.2021.106658] [Reference Citation Analysis]
|
| 4 |
Chen XL, Mao JW, Wang YD. Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future. World J Gastrointest Pathophysiol 2020; 11(3): 43-56 [PMID: 32435521 DOI: 10.4291/wjgp.v11.i3.43] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 5 |
Sood A, Singh A, Sudhakar R, Midha V, Mahajan R, Mehta V, Gupta YK, Kaur K. Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn's disease: the Indian experience. Intest Res 2020;18:184-91. [PMID: 32092799 DOI: 10.5217/ir.2019.00094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 6 |
Motoya S, Tanaka H, Shibuya T, Osada T, Yamamoto T, Hongo H, Mizuno C, Saito D, Aoyama N, Kobayashi T, Ito H, Tanida S, Nojima M, Kokuma S, Hosoi E. Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study. BMC Gastroenterol. 2019;19:196. [PMID: 31752695 DOI: 10.1186/s12876-019-1110-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 7 |
Hattori K. Roles of the fibrinolytic system in inflammatory bowel diseases. Nihon Kessen Shiketsu Gakkaishi 2017;28:618-622. [DOI: 10.2491/jjsth.28.618] [Reference Citation Analysis]
|
| 8 |
Tanida S, Ozeki K, Mizoshita T, Tsukamoto H, Katano T, Kataoka H, Kamiya T, Joh T. Managing refractory Crohn's disease: challenges and solutions. Clin Exp Gastroenterol 2015;8:131-40. [PMID: 25914555 DOI: 10.2147/CEG.S61868] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 9 |
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 10 |
Mizoshita T, Tanida S, Kusumoto S, Ozeki K, Tsukamoto H, Ebi M, Mori Y, Kataoka H, Kamiya T, Joh T. Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia. Clin J Gastroenterol 2012;5:302-6. [PMID: 26182398 DOI: 10.1007/s12328-012-0314-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 11 |
Itagaki M, Saruta M, Iinuma T, Arihiro S, Kato T, Tajiri H. Infliximab- and immunosuppressant-resistant Crohn's disease successfully treated with adsorptive granulocyte apheresis combined with prednisolone. Case Rep Gastroenterol 2012;6:118-23. [PMID: 22761605 DOI: 10.1159/000334428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 12 |
Hisamatsu T, Hibi T. 6. Progress in Management of Crohn's Disease. J Jpn Soc Intern Med 2011;100:85-95. [DOI: 10.2169/naika.100.85] [Reference Citation Analysis]
|
| 13 |
Suzuki Y. An Update on the Treatment of Crohn's Disease. Journal of Japan Society of Coloproctology 2010;63:863-868. [DOI: 10.3862/jcoloproctology.63.863] [Reference Citation Analysis]
|
| 14 |
Matsuda C, Ito T, Song J, Mizushima T, Tamagawa H, Kai Y, Hamanaka Y, Inoue M, Nishida T, Matsuda H, Sawa Y. Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis. Clin Exp Immunol 2007;148:348-59. [PMID: 17437423 DOI: 10.1111/j.1365-2249.2007.03345.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 15 |
Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577 [PMID: 17171783 DOI: 10.3748/wjg.v12.i47.7568] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 16 |
Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, Ost A, Hittel N, Saniabadi A, Löfberg R. Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis 2006;21:493-504. [PMID: 16538495 DOI: 10.1007/s00384-005-0069-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 17 |
Watanabe K, Oshitani N, Kamata N, Inagawa M, Yamagami H, Higuchi K, Arakawa T. Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis. Aliment Pharmacol Ther Symp Series 2006;2:147-52. [DOI: 10.1111/j.1746-6342.2006.00038.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 18 |
Yamamoto T, Umegae S, Matsumoto K. Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis. World J Gastroenterol 2006; 12(4): 520-525 [PMID: 16489663 DOI: 10.3748/wjg.v12.i4.520] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 32] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 19 |
Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, Shimoyama T. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005;100:1362-9. [PMID: 15929771 DOI: 10.1111/j.1572-0241.2005.41089.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 20 |
Ohmori T, Yamagiwa A, Nakamura I, Nishikawa K, Saniabadi AR. Treatment of pyoderma gangrenosum associated with Crohn's disease. Am J Gastroenterol 2003;98:2101-2. [PMID: 14499797 DOI: 10.1111/j.1572-0241.2003.07657.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
|
